ArticleJournal of molecular and cellular cardiology2019
The role of fibroblast - Cardiomyocyte interaction for atrial dysfunction in HFpEF and hypertensive heart disease.
Article in Journal of molecular and cellular cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications.Nature reviews. Cardiology · 2024Review
- Cardiac cell senescence: molecular mechanisms, key proteins and therapeutic targets.Cell death discovery · 2024Review
- Article
- Hypertensive Heart Disease: A Narrative Review Series-Part 2: Macrostructural and Functional Abnormalities.Journal of clinical medicine · 2023Review
- Interaction effect of hypertension and obesity on left atrial phasic function: a three-dimensional echocardiography study.Quantitative imaging in medicine and surgery · 2023Article
- Left Atrial Myocardium in Arterial Hypertension.Cells · 2022Review
- Heart failure with preserved ejection fraction: An alternative paradigm to explain the clinical implications of atrial fibrillation.Heart rhythm O2 · 2021Article
- Ultrasonic-Assisted Enzymolysis Extraction and Protective Effect on Injured Cardiomyocytes in Mice of Flavonoids fromMolecules (Basel, Switzerland) · 2021Article
- Right-ventricular dysfunction in HFpEF is linked to altered cardiomyocyte CaESC heart failure · 2021Article
- Effects of different exercise modalities on cardiac dysfunction in heart failure with preserved ejection fraction.ESC heart failure · 2021Article
- Implications of SGLT Inhibition on Redox Signalling in Atrial Fibrillation.International journal of molecular sciences · 2021Review
- Reversible Treatment of Pressure Overload-Induced Left Ventricular Hypertrophy throughAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Oxidative Stress and Inflammatory Modulation of CaAntioxidants (Basel, Switzerland) · 2020Article
- The molecular mechanisms associated with the physiological responses to inflammation and oxidative stress in cardiovascular diseases.Biophysical reviews · 2020Review
- Human pluripotent stem cell-derived cardiac stromal cells and their applications in regenerative medicine.Stem cell research · 2020Review
- Cardiac Fibroblast to Myofibroblast Phenotype Conversion-An Unexploited Therapeutic Target.Journal of cardiovascular development and disease · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 3 countries.
Funding
Abstract
aimsAtrial contractile dysfunction is associated with increased mortality in heart failure (HF). We have shown previously that a metabolic syndrome-based model of HFpEF and a model of hypertensive heart disease (HHD) have impaired left atrial (LA) function in vivo (rat). In this study we postulate, that left atrial cardiomyocyte (CM) and cardiac fibroblast (CF) paracrine interaction related to the inositol 1,4,5-trisphosphate signalling cascade is pivotal for the manifestation of atrial mechanical dysfunction in HF and that quantitative atrial remodeling is highly disease-dependent. METHODS AND
resultsDifferential remodeling was observed in HHD and HFpEF as indicated by an increase of atrial size in vivo (HFpEF), unchanged fibrosis (HHD and HFpEF) and a decrease of CM size (HHD). Baseline contractile performance of rat CM in vitro was enhanced in HFpEF. Upon treatment with conditioned medium from their respective stretched CF (CM-SF), CM (at 21 weeks) of WT showed increased Ca
conclusionsAtrial remodeling is a complex entity that is highly disease and stage dependent. The activity of fibrosis related to paracrine interaction (e.g. ET-1) might contribute to in vitro and in vivo atrial dysfunction. However, during later stages of disease, ECC is impaired unrelated to CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.